Emerging Concepts and Human Trials in Alpha-1-Antitrypsin Deficiency Liver Disease

Abstract

In α-1-antitrypsin (AAT) deficiency, individuals homozygous for the AAT mutant Z gene synthesize large quantities of mutant Z protein in the liver, which folds improperly during biogenesis and is retained within the hepatocytes rather than appropriated secreted. This accumulation of mutant Z protein triggers an intracellular injury cascade causing cell death in the population of hepatocytes with the largest accumulations of Z protein. Hepatocellular proliferation, hepatic fibrosis, and hepatocellular cancer in some individuals can be the result. New insights from basic science studies have now allowed the application of new biotechnologies to this previously untreatable disease. Specifically, drugs designed to accelerate the intracellular removal of the mutant Z protein (autophagy enhancers) and siRNA strategies designed to shut down synthesis of the toxic, mutant Z protein, are now in human trials. Other approaches, such as gene correction, cell therapy, and antifibrotic drugs are in preclinical development.

Keywords

alpha-1-antitrypsin - autophagy - liver disease - siRNA - endoplasmic reticulum-associated degradation

• References

• 1 Teckman JH, Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Rev Gastroenterol Hepatol 2015; 9 (02) 261-268
• 2 Teckman JH, Gilmore R, Perlmutter DH. Role of ubiquitin in proteasomal degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol 2000; 278 (01) G39-G48
• 3 Teckman JH, Rosenthal P, Abel R. , et al; Childhood Liver Disease Research Network (ChiLDReN). Baseline analysis of a young α-1-antitrypsin deficiency liver disease cohort reveals frequent portal hypertension. J Pediatr Gastroenterol Nutr 2015; 61 (01) 94-101
• 4 Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with a(1)-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 2012; 10 (06) 575-580
• 5 Perlmutter DH. Alpha-1-antitrypsin deficiency: diagnosis and treatment. Clin Liver Dis 2004; 8 (04) 839-859 , viii–ix viii–ix.
• 6 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168 (07) 818-900
• 7 Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294 (24) 1316-1321
• 8 Sveger T. Alpha 1-antitrypsin deficiency in early childhood. Pediatrics 1978; 62 (01) 22-25
• 9 Eriksson S. Alpha 1-antitrypsin deficiency. J Hepatol 1999; 30 (Suppl. 01) 34-39
• 10 An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of alphalAT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology 2005; 41 (01) 160-167
• 11 Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology 1995; 22 (02) 514-517
• 12 Cruz PE, Mueller C, Cossette TL. , et al. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest 2007; 87 (09) 893-902
• 13 Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 1988; 77 (06) 847-851
• 14 Mowat AP. Alpha 1-antitrypsin deficiency (PiZZ): features of liver involvement in childhood. Acta Paediatr Suppl 1994; 393: 13-17
• 15 Pittschieler K, Massi G. Alpha 1 antitrypsin deficiency in two population groups in north Italy. Padiatr Padol 1988; 23 (04) 307-311
• 16 Eriksson S. Alpha-1-antitrypsin deficiency: natural course and therapeutic strategies. In: Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA. , eds. Falk Symposium 115: Liver Cirrhosis and its Development. Dordrecht: Kluwer Academic Publishers; 2001: 307-315
• 17 Eriksson S. A 30-year perspective on alpha 1-antitrypsin deficiency. Chest 1996; 110 (6, Suppl) 237S-242S
• 18 Eriksson S, Lindmark B, Olsson S. Lack of association between hemochromatosis and alpha-antitrypsin deficiency. Acta Med Scand 1986; 219 (03) 291-294
• 19 He XX, Li Y, Ren HP, Tian DA, Lin JS. [2010 guideline for the management of hepatocellular carcinoma recommended by the American Association for the Study of Liver Diseases]. Zhonghua Gan Zang Bing Za Zhi 2011; 19 (04) 249-250
• 20 Rudnick DA, Shikapwashya O, Blomenkamp K, Teckman JH. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 2006; 44 (04) 976-982
• 21 Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A 1994; 91 (19) 9014-9018
• 22 Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357 (6379): 605-607
• 23 Teckman JH, Perlmutter DH. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 2000; 279 (05) G961-G974
• 24 Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 2004; 39 (04) 1048-1055
• 25 Lindblad D, Blomenkamp K, Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology 2007; 46 (04) 1228-1235
• 26 Sifers RN. Medicine. Clearing conformational disease. Science 2010; 329 (5988): 154-155
• 27 Sifers RN. Resurrecting the protein fold for disease intervention. Chem Biol 2013; 20 (03) 298-300
• 28 Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996; 271 (37) 22791-22795
• 29 Teckman JH, Perlmutter DH. The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem 1996; 271 (22) 13215-13220
• 30 Perlmutter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med 2011; 62: 333-345
• 31 Sifers RN. Intracellular processing of alpha1-antitrypsin. Proc Am Thorac Soc 2010; 7 (06) 376-380
• 32 Tang Y, Fickert P, Trauner M, Marcus N, Blomenkamp K, Teckman J. Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease. Am J Physiol Gastrointest Liver Physiol 2016; 311 (01) G156-G165
• 33 Miller SD, Greene CM, McLean C. , et al. Tauroursodeoxycholic acid inhibits apoptosis induced by Z alpha-1 antitrypsin via inhibition of Bad. Hepatology 2007; 46 (02) 496-503
• 34 Pastore N, Blomenkamp K, Annunziata F. , et al. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. EMBO Mol Med 2013; 5 (03) 397-412
• 35 Kaushal S, Annamali M, Blomenkamp K. , et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 2010; 235 (06) 700-709
• 36 Hidvegi T, Ewing M, Hale P. , et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329 (5988): 229-232
• 37 Marcus NY, Blomenkamp K, Ahmad M, Teckman JH. Oxidative stress contributes to liver damage in a murine model of alpha-1-antitrypsin deficiency. Exp Biol Med (Maywood) 2012; 237 (10) 1163-1172
• 38 Brunt EM, Blomenkamp K, Ahmed M, Ali F, Marcus N, Teckman J. Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency. J Pediatr Gastroenterol Nutr 2010; 51 (05) 626-630
• 39 Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem 2002; 277 (09) 6771-6774
• 40 Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 2000; 97 (04) 1796-1801
• 41 Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem 2012; 287 (45) 38265-38278
• 42 Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr 2004; 39 (01) 34-37
• 43 Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R. Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema. Am J Respir Cell Mol Biol 2004; 31 (02) 133-139
• 44 Wang Y, Perlmutter DH. Targeting intracellular degradation pathways for treatment of liver disease caused by α1-antitrypsin deficiency. Pediatr Res 2014; 75 (1-2): 133-139
• 45 Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol 2004; 286 (05) G851-G862